Journal article
Complement in monoclonal antibody therapy of cancer
Immunologic research, Vol.59(1-3), pp.203-210
08/01/2014
DOI: 10.1007/s12026-014-8542-z
PMCID: PMC4381956
PMID: 24906530
Abstract
Monoclonal antibodies (mAb) have been used as targeted treatments against cancer for more than a decade, with mixed results. Research is needed to understand mAb mechanisms of action with the goal of improving the efficacy of currently used mAbs and guiding the design of novel mAbs. While some mAb-induced tumor cell killing is a result of direct effects on tumor cell signaling, mAb opsonization of tumor cells also triggers activation of immune responses due to complement activation and engagement of antibody receptors on immune effector cells. In fact, complement has been shown to play an important role in modulating the anti-tumor activity of many mAb through complement-dependent cytotoxicity, antibody-dependent cytotoxicity, and through indirect effects by modulating the tumor microenvironment. Complement activity can have both agonistic and antagonistic effects on these processes. How the balance of such effects impacts on the clinical efficacy of mAb therapy remains unclear. In this review, we discuss the mAbs currently approved for cancer treatment and examine how complement can impact their efficacy with a focus on how this information might be used to improve the clinical efficacy of mAb treatment.
Details
- Title: Subtitle
- Complement in monoclonal antibody therapy of cancer
- Creators
- Laura M. Rogers - University of IowaSuresh Veeramani - University of IowaGeorge J. Weiner - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Immunologic research, Vol.59(1-3), pp.203-210
- Publisher
- Humana Press Inc
- DOI
- 10.1007/s12026-014-8542-z
- PMID
- 24906530
- PMCID
- PMC4381956
- ISSN
- 0257-277X
- eISSN
- 1559-0755
- Number of pages
- 8
- Grant note
- T32HL007344 / NATIONAL HEART, LUNG, AND BLOOD INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI) T32 HL007344 / NHLBI NIH HHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)
- Language
- English
- Date published
- 08/01/2014
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Holden Comprehensive Cancer Center; Internal Medicine
- Record Identifier
- 9984359911602771
Metrics
14 Record Views